First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United States–Based Cost-Effectiveness Analysis

2015160 citationsJournal Article

Authors

Daniel A. Goldstein · Emory Healthcare

Qiushi Chen · Emory Healthcare

Turgay Ayer · Emory Healthcare

David H. Howard · Emory Healthcare

Joseph Lipscomb · Emory Healthcare

Bassel F. El‐Rayes · Emory Healthcare

Christopher R. Flowers ·

Abstract

Bevacizumab provides minimal incremental benefit at high incremental cost per QALY in both the first- and second-line settings of metastatic colorectal cancer treatment.

Topics & Keywords

Colorectal Cancer Treatments and Studies Gastric Cancer Management and Outcomes Economic and Financial Impacts of Cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 33, Issue 10, pp. 1112-1118

DOI: 10.1200/jco.2014.58.4904

Field-Weighted Citation Impact: 10.98